Drug development

We go beyond expectations to deliver dedicated, hands-on, and tailored scientific support — ensuring every project meets the highest standards of excellence.

Lead identification

With unmatched predictive power, iCAN R&D allows testing of many compounds in representative models quickly and efficiently to identify those with potential therapeutic effects.

Lead optimization

iCAN R&D can be used to narrow down the number of lead compounds and optimize them for further development as clinical drug candidates.

Candidate drug selection

iCAN R&D read-outs provide a more comprehensive decision base in the final selection stages of a candidate drug, and can identify the most clinically relevant patient subgroups using large representative tumoroid biobanks.

Clinical trial stratification

iCAN R&D is a valuable companion diagnostic tool in drug trials, identifying responders and non-responders to the drug. Selecting patients who are likely to respond to a novel drug can significantly reduce the trial size, duration, and cost.

Studying drug resistance in tumors

Many cancers develop drug resistance over time and become hard to treat. By analyzing tumoroids, new compounds can be discovered to overcome this resistance.

Testing of drug combinations

Flexible combinatorial drug screening of tumoroids can greatly facilitate discovery of more effective therapy regimens.

Target phenotyping -> Model selection -> Drug screening

Spatial proteomics using multiplex immunohistochemistry (CD133-P53-CAIX-CD44)

Drug development

We go beyond expectations to deliver dedicated, hands-on, and tailored scientific support — ensuring every project meets the highest standards of excellence.

Lead identification

With unmatched predictive power, iCAN R&D allows testing of many compounds in representative models quickly and efficiently to identify those with potential therapeutic effects.

Lead optimization

iCAN R&D can be used to narrow down the number of lead compounds and optimize them for further development as clinical drug candidates.

Candidate drug selection

iCAN R&D read-outs provide a more comprehensive decision base in the final selection stages of a candidate drug, and can identify the most clinically relevant patient subgroups using large representative tumoroid biobanks.

Stratification of patients in clinical studies

iCAN R&D is a valuable companion diagnostic tool in drug trials, identifying responders and non-responders to the drug. Selecting patients who are likely to respond to a novel drug can significantly reduce the trial size, duration, and cost.

Studying drug resistance in tumors

Many cancers develop drug resistance over time and become hard to treat. By analyzing tumoroids, new compounds can be discovered to overcome this resistance.

Testing of drug combinations

Flexible combinatorial drug screening of tumoroids can greatly facilitate discovery of more effective therapy regimens.

iCAN R&D offers ultrafast and large-scale tailored testing and analysis providing reliable data

We are actively establishing new tumoroid biobanks from colorectal and pancreatic cancers to identify better drugs.

Large pharmacological databases reveal clinical potential

“Oncosyne’s iCAN platform has been instrumental in advancing our clinical development of arfolitixorin. The tumoroid-based experiments not only confirmed the findings of the phase 3 AGENT trial but also provided novel insights into arfolitixorin’s mechanism of action, optimal drug combinations, and potential predictive biomarkers.

Importantly, I believe these data played a key role in supporting discussions with regulatory authorities and ultimately helped us secure approval for our new phase 1b/2 dose-optimization study (NCT06922383)”

Roger Tell

Chief Medical Officer, Isofol Medical

How can we assist you?

If you’re interested in how iCAN R&D can assist with your project, reach out to us.

Contact us